OTCM
TCHBF
Market cap3.76bUSD
, Last price
Name
Tecan Group AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tecan Group AG delivers advanced laboratory instruments and complete solutions to a diverse client base, including pharmaceutical and biotechnology companies, academic research institutions, and both forensic and diagnostic laboratories. The company operates through two primary segments: Life Sciences Business and Partnering Business. Its comprehensive product range features liquid handling and automation systems, microplate readers and washers, various consumables, next-generation sequencing (NGS) reagents, immunoassays, microbodies, and specialized software. Key offerings include Tecan Laberwax, an innovative automation solution, and Resolvex, an intelligent sample preparation system utilized in fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. Furthermore, Tecan develops and manufactures essential components like precision pumps, valves, robotic arms, and developer software, supplying these to other laboratory instrument manufacturers for use in life science research, diagnostics, and other industries. Its automation portfolio also includes platforms like Synergence and renowned instruments such as Freedom EVO and Fluent. With a global presence, Tecan Group AG conducts operations across Switzerland, Europe, North America, Asia, and other international markets. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.
Related entities
Subsidiaries (2)
Tecan Sales International GmbH
Tecan Trading AG
Key people
Monica Manotas
Chief Executive Officer, Director · since 2025
Tania Micki
Chief Financial Officer, Member of the Management Board · since 2020
Ingrid Purgstaller
Chief People Officer, Member of the Management Board · since 2020
Andreas Wilhelm
Executive Vice President - Legal, Quality and Regulatory Affairs, General Counsel, Member of the Management Board, Secretary of the Board of Directors · since 2025
Wael Yared
Executive Vice President, Chief Technology Officer, Head Research and Development, Member of the Management Board · since 2019
Mukta Acharya
Executive Vice President, Head of the Life Sciences Business Division, Member of the Management Board · since 2024
Ralf Griebel
Executive Vice President, Head of the Partnering Business division, Member of the Management Board · since 2020
Ulrich Kanter
Executive Vice President, Global Head of Operations & IT, Member of the Management Board · since 2021
Erik Norstrom
Executive Vice President, Head of Corporate Development, Member of the Management Board · since 2017
Matthias Gillner
Non-Executive Director · since 2023
Non-Executive Director · since 2018
Myra Eskes
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2011
Non-Executive Independent Director · since 2013
Headquarters & legal address
Seestrasse 103
Männedorf, ZH 8708
CH
Männedorf, ZH 8708
CH
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||